Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Hypofractionated Radiotherapy in MSI-H/dMMR Rectal Cancer
NCT04636008Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2020
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in rectal cancer, sponsored by West China Hospital of Sichuan University. Started Aug 2020; status: recruiting.
02
Drugs
sintilimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04636008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04636008.